Gilead to Acquire Arcellx for $7.8B, Securing CAR-T Therapy Rights
Arcellx agreed to be acquired by Gilead for $7.8 billion to secure rights to its anito-cel anti-BCMA CAR T therapy for relapsed/refractory multiple myeloma. Fast Track–designated anito-cel could generate $658 million in 2032 sales across eight markets and has entered Phase III iMMagine-2 and -3 trials.
1. Acquisition Details
On February 23, Gilead Sciences entered a definitive agreement to acquire Arcellx for $7.8 billion, valuing the company’s CAR T pipeline. The deal secures exclusive rights to anitocabtagene autoleucel (anito-cel) and builds on Kite Pharma’s prior expansion of its collaboration with Arcellx.
2. Pipeline and Trials
Anito-cel received Fast Track designation on February 28 following robust responses in the iMMagine-1 trial for patients with at least three prior regimens. Global projections estimate $658 million in 2032 sales across the US, EU5, UK, Japan and China, while Phase III iMMagine-2 and iMMagine-3 studies are underway to evaluate earlier lines of therapy.
3. Manufacturing Advantages and Outlook
Arcellx leverages Kite’s infrastructure to achieve a 17-day manufacturing turnaround, compared with the 30-day industry benchmark, using a compact D-domain binder for stable CAR expression and reduced toxic signalling. These efficiencies, combined with lower rates of severe cytokine release syndrome and neurotoxicity, position anito-cel for competitive pricing and broader patient access, though scaling capacity and securing reimbursement remain key risks.